Drug Utilization Pattern of Proton Pump Inhibitors in Patients with Acid Peptic Disease and Comorbidities in India: A Real-World Electronic Medical Records-Based Study - PubMed
6 hours ago
- #Acid Peptic Disease
- #Real-World Evidence
- #Proton Pump Inhibitors
- This real-world study analyzed electronic medical records from four Indian outpatient clinics (2017-2020) to understand proton pump inhibitor (PPI) utilization in adult acid peptic disease (APD) patients with comorbidities.
- Among 687 APD patients (mean age 47.8 years, 56.6% male), pantoprazole was the most commonly prescribed PPI (51.7%), followed by esomeprazole (20.2%), rabeprazole (13.0%), lansoprazole (9.2%), and omeprazole (6.0%).
- PPIs were frequently co-prescribed with medications for comorbidities, such as antidiabetics, antiplatelets, antihypertensives, antibiotics, and antithyroid drugs.
- Pantoprazole showed higher treatment adherence compared to other PPIs at follow-up visits.
- All APD symptoms significantly reduced at the second follow-up visit compared to baseline across all PPI groups (p < 0.05), and all PPIs were well-tolerated with expected adverse event profiles.
- The study concluded that all PPIs are effective and well-tolerated for managing APD in patients with comorbidities, with pantoprazole being the most co-prescribed and preferred PPI in this Indian setting.